SANA BIOTECHNOLOGY INC
NASDAQ: SANA (Sana Biotechnology, Inc.)
Last update: 13 hours ago4.30
0.28 (6.97%)
| Previous Close | 4.02 |
| Open | 4.08 |
| Volume | 3,792,954 |
| Avg. Volume (3M) | 4,802,084 |
| Market Cap | 1,145,374,336 |
| Price / Book | 4.79 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -0.880 |
| Total Debt/Equity (MRQ) | 43.67% |
| Current Ratio (MRQ) | 3.40 |
| Operating Cash Flow (TTM) | -206.18 M |
| Levered Free Cash Flow (TTM) | -118.45 M |
| Return on Assets (TTM) | -23.84% |
| Return on Equity (TTM) | -71.44% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Sana Biotechnology, Inc. | Bearish | Mixed |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.75 |
|
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 among others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.46% |
| % Held by Institutions | 89.37% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Integral Health Asset Management, Llc | 30 Sep 2025 | 2,000,000 |
| Crestline Management, Lp | 30 Sep 2025 | 1,820,937 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 9.00 (HC Wainwright & Co., 109.30%) | Buy |
| Median | 8.00 (86.05%) | |
| Low | 6.00 (Wedbush, 39.54%) | Buy |
| Average | 7.67 (78.37%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 4.36 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 07 Nov 2025 | 9.00 (109.30%) | Buy | 4.09 |
| Wedbush | 07 Nov 2025 | 6.00 (39.53%) | Buy | 4.09 |
| 24 Sep 2025 | 5.00 (16.28%) | Buy | 3.41 | |
| Citizens | 30 Oct 2025 | 8.00 (86.05%) | Buy | 4.90 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 24 Nov 2025 | Announcement | Sana Biotechnology to Present at December 2025 Investor Conferences |
| 06 Nov 2025 | Announcement | Sana Biotechnology Reports Third Quarter 2025 Financial Results and Business Updates |
| 04 Nov 2025 | Announcement | Sana Biotechnology to Present at the TD Cowen Immunology & Inflammation Summit |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |